Phase 3 N=952 A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
Allergy
Primary: Average Total Combined Score (TCS) During the Birch Pollen Season (BPS) — 5.88; 4.60 score on a scale — p=0.0004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=617 Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale
Phase 2 N=240 Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
Allergic Rhinitis · Rhinoconjunctivitis
Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)
Phase 3 N=353 Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
Allergic Rhinitis · Conjunctivitis
Primary: Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo — 7.503; 8.498 Scores on a Scale — p=0.0497
N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Phase 2 N=606 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS — -3.57; -2.31; -2.96; -1.48 score on a scale
Phase 2 N=217 Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Allergic Rhinitis · Conjunctivitis
Primary: Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at…
Phase 4 N=102 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen
Seasonal Allergy
Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…
Phase 4 N=93 The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation
Allergic Rhinoconjunctivitis
Primary: Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment. — 2.3; 2.2 Scores on a scale
Phase 4 N=255 A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
Rhinitis
Primary: Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes) — 7.4; 6.7; 8.5; 7.5 units on a scale
Phase 3 N=671 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period. — -1.74; -1.75; -0.72 Units on a scale — p=<0.0001
Phase 3 N=337 Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients
Seasonal Allergic Rhinitis
Primary: Mean Nasal Symptom Score — 3.66; 4.69 score — p=<0.001
N/A N=196 Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Birch Pollen Allergy
Primary: Average of the Combined Rhinoconjunctivitis Symptom and Medication Score (RSMS) Obtained Daily During the Birch Pollen Season — 0.853; 0.795; 0.959 units on a scale
Phase 3 N=1,079 Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale
Phase 3 N=1,214 Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale
Phase 2 N=46 Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
Allergic Rhinitis
Primary: Total Nasal Symptom Score After Nasal Allergen Challenge (NAC) — 3.37; 4.71 score on a scale — p=<0.05
Phase 3 N=716 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Allergic Rhinitis
Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001
Phase 1 N=89 Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
Seasonal Allergic Rhinitis
Primary: Average of Rhinoconjunctivitis Total Symptom Score (ARTSS) ]0-4] Hours — 4.88; 6.84 Units on a scale (range: 0 to 18) — p=0.0003
Phase 2 N=89 Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSS — -1.17; -0.69; -2.43; -1.65 units on a scale
Phase 2 N=47 Effects of Broccoli Sprout Extract on Allergy Rhinitis
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Phase 3 N=547 Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial
Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…
Phase 3 N=1,365 Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Phase 3 N=1,577 Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 Weeks — -0.24; -0.37; -0.47 Units on a Scale
Phase 2 N=601 Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Subject-rated Reflective TNSS — -1.84; -1.71; -1.47; -0.99 score on a scale
Phase 3 N=1,992 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Phase 3 N=445 A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
Allergy
Primary: Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS) — 7.10; 5.22 score on a scale — p=0.0036
Phase 3 N=473 Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
Allergic Rhinitis Due to Grass Pollens
Primary: Combined Score (CS) — 0.32; 0.45 Units on a scale (range: 0 to 3) — p=0.0003
Phase 4 N=418 Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I — -3.46; -6.58; -5.65 units on a scale — p=<0.001